40 related articles for article (PubMed ID: 30656528)
21. Evaluation of ERG and PTEN protein expression in cribriform architecture prostate carcinomas.
Downes MR; Satturwar S; Trudel D; van der Kwast TH
Pathol Res Pract; 2017 Jan; 213(1):34-38. PubMed ID: 27913052
[TBL] [Abstract][Full Text] [Related]
22. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
23. SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
Hernández-Llodrà S; Segalés L; Juanpere N; Marta Lorenzo T; Salido M; Nonell L; David López T; Rodríguez-Vida A; Bellmunt J; Fumadó L; Cecchini L; Lloreta-Trull J
Prostate; 2021 Dec; 81(16):1267-1277. PubMed ID: 34533858
[TBL] [Abstract][Full Text] [Related]
24. Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.
Elfandy H; Armenia J; Pederzoli F; Pullman E; Pertega-Gomes N; Schultz N; Viswanathan K; Vosoughi A; Blattner M; Stopsack KH; Zadra G; Penney KL; Mosquera JM; Tyekucheva S; Mucci LA; Barbieri C; Loda M
Mol Cancer Res; 2019 Feb; 17(2):446-456. PubMed ID: 30333152
[TBL] [Abstract][Full Text] [Related]
25. Clinical implications of PTEN loss in prostate cancer.
Jamaspishvili T; Berman DM; Ross AE; Scher HI; De Marzo AM; Squire JA; Lotan TL
Nat Rev Urol; 2018 Apr; 15(4):222-234. PubMed ID: 29460925
[TBL] [Abstract][Full Text] [Related]
26. ERG expression in prostate cancer: biological relevance and clinical implication.
Abou-Ouf H; Zhao L; Bismar TA
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1781-93. PubMed ID: 26711283
[TBL] [Abstract][Full Text] [Related]
27. Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer.
Rodrigues LU; Rider L; Nieto C; Romero L; Karimpour-Fard A; Loda M; Lucia MS; Wu M; Shi L; Cimic A; Sirintrapun SJ; Nolley R; Pac C; Chen H; Peehl DM; Xu J; Liu W; Costello JC; Cramer SD
Cancer Res; 2015 Mar; 75(6):1021-34. PubMed ID: 25770290
[TBL] [Abstract][Full Text] [Related]
28. ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer.
Gsponer JR; Braun M; Scheble VJ; Zellweger T; Bachmann A; Perner S; Vlajnic T; Srivastava M; Tan SH; Dobi A; Sesterhenn IA; Srivastava S; Bubendorf L; Ruiz C
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):126-31. PubMed ID: 24469092
[TBL] [Abstract][Full Text] [Related]
29. ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease.
Teng LH; Wang C; Bégin LR; Dolph M; Yilmaz A; Trpkov K; Donnelly B; Bismar TA
Urology; 2013 Aug; 82(2):394-9. PubMed ID: 23746715
[TBL] [Abstract][Full Text] [Related]
30. Brain metastases from prostate cancer: an 11-year analysis in the MRI era with emphasis on imaging characteristics, incidence, and prognosis.
Hatzoglou V; Patel GV; Morris MJ; Curtis K; Zhang Z; Shi W; Huse J; Rosenblum M; Holodny AI; Young RJ
J Neuroimaging; 2014; 24(2):161-6. PubMed ID: 23279641
[TBL] [Abstract][Full Text] [Related]
31. Ectopic pituitary adenoma of the clivus presenting with apoplexy: case report and review of the literature.
Mudd PA; Hohensee S; Lillehei KO; Kingdom TT; Kleinschmidt-Demasters BK
Clin Neuropathol; 2012; 31(1):24-30. PubMed ID: 22192701
[TBL] [Abstract][Full Text] [Related]
32. The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers.
Guo CC; Wang Y; Xiao L; Troncoso P; Czerniak BA
Hum Pathol; 2012 May; 43(5):644-9. PubMed ID: 21937078
[TBL] [Abstract][Full Text] [Related]
33. Brain metastasis from prostate carcinoma: The M. D. Anderson Cancer Center experience.
Tremont-Lukats IW; Bobustuc G; Lagos GK; Lolas K; Kyritsis AP; Puduvalli VK
Cancer; 2003 Jul; 98(2):363-8. PubMed ID: 12872358
[TBL] [Abstract][Full Text] [Related]
34. Current State of ERG as Biomarker in Prostatic Adenocarcinoma.
Acs B; Szarvas T; Szekely N; Nyirady P; Szasz AM
Curr Cancer Drug Targets; 2015; 15(8):643-51. PubMed ID: 26452381
[TBL] [Abstract][Full Text] [Related]
35. Prostatic adenocarcinoma CNS parenchymal and dural metastases: alterations in ERG, CHD1 and MAP3K7 expression.
Ormond DR; Kleinschmidt-DeMasters BK; Cavalcante D; Smith EE; Cramer SD; Lucia MS
J Neurooncol; 2019 Apr; 142(2):319-325. PubMed ID: 30656528
[TBL] [Abstract][Full Text] [Related]
36. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
37. ERG protein expression as a biomarker of prostate cancer.
Falzarano SM; Magi-Galluzzi C
Biomark Med; 2013 Dec; 7(6):851-65. PubMed ID: 24266818
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
